Compare LWAY & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWAY | XOMA |
|---|---|---|
| Founded | 1986 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 308.6M |
| IPO Year | 1987 | N/A |
| Metric | LWAY | XOMA |
|---|---|---|
| Price | $22.11 | $24.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $35.00 | ★ $63.25 |
| AVG Volume (30 Days) | 49.7K | ★ 563.3K |
| Earning Date | 03-13-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.74 | ★ 0.82 |
| Revenue | ★ $204,069,000.00 | $47,106,000.00 |
| Revenue This Year | $15.23 | $77.29 |
| Revenue Next Year | $13.72 | $29.30 |
| P/E Ratio | $29.61 | ★ $28.69 |
| Revenue Growth | 12.14 | ★ 118.02 |
| 52 Week Low | $19.50 | $18.35 |
| 52 Week High | $34.20 | $39.92 |
| Indicator | LWAY | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 39.03 |
| Support Level | $21.25 | $22.29 |
| Resistance Level | $22.50 | $27.87 |
| Average True Range (ATR) | 0.64 | 1.48 |
| MACD | 0.06 | -0.20 |
| Stochastic Oscillator | 40.61 | 23.57 |
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.